@article {7924,
	title = {Anthracycline-based adjuvant chemotherapy in early-stage uterine sarcomas: Long-term results of a single institution experience},
	journal = {European Journal of Gynaecological Oncology},
	volume = {28},
	year = {2007},
	note = {Cited By :6Export Date: 21 February 2017},
	month = {2007},
	pages = {109 - 116},
	abstract = {Purpose of investigation: Uterine sarcomas are rare neoplasms characterized by a high rate of local recurrences and distant metastases. The role of chemotherapy in early-stage completely resected disease remains controversial. Methods: Thirty-one patients with Stage I or II uterine sarcomas, referred to our center for adjuvant chemotherapy, received anthracycline-based regimens. Seventeen (54.8\%) patients received ifosfamide, etoposide and epirubicin, six (19.4\%) were treated with doxorubicin and carboplatin, three (9.6\%) were administered doxorubicin and ifosfamide, while five (16.1\%) patients received various anthracycline-based regimens. Results: With a median follow-up of 82 months disease recurred in 12 (38.7\%) patients. Five-year survival probability is estimated at 54\%. Both median overall survival and time to progression for all patients have not been reached yet. Patients who received ifosfamide-containing regimens had a statistically significant benefit in overall survival (p <= 0.05) when compared with those treated with non-ifosfamide-containing regimens. Conclusion: Our data suggest a potential role for anthracycline- and ifosfamide-containing chemotherapy in the adjuvant setting for early-stage uterine sarcomas.},
	keywords = {Adjuvant chemotherapy, Anthracyclines, Early-stage uterine sarcomas, Ifosfamide},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-34247881829\&partnerID=40\&md5=f03dd4a22b7b9bcc125058aeb7b63e3d},
	author = {Papadimitriou, C.A. and Zorzou, M.P. and Markaki, S. and Rodolakis, A. and Voulgaris, Z. and Bozas, G. and Kastritis, E. and Bamias, A. and Gika, D. and Dimopoulos, M.A.}
}
